36 min listen
Evolution of HER2-Targeted Therapy in Gastroesophageal Adenocarcinoma
Evolution of HER2-Targeted Therapy in Gastroesophageal Adenocarcinoma
ratings:
Length:
29 minutes
Released:
Apr 4, 2024
Format:
Podcast episode
Description
Did you know that HER2-targeted therapy is an established treatment option for patients with HER2-positive metastatic gastric/gastroesophageal junction (GEJ) cancer? Credit available for this activity expires: 3/29/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000593?ecd=bdc_podcast_libsyn_mscpedu
Released:
Apr 4, 2024
Format:
Podcast episode
Titles in the series (100)
Acute Myeloid Leukemia Beyond FLT3 and IDH: The Role of Non-Targetable Driver Mutations: Do you understand the role of non-targetable driver mutations in the management of acute myeloid leukemia (AML)? Credit available for this activity expires: 5/1/2024 Earn Credit / Learning Objectives & Disclosures: by Keeping Current CME